Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- Johnson & Johnson (NYSE:JNJ) and a consortium of global partners announced results from the primary analysis of a Phase 2b HIV vaccine trial, Imbokodo study.
- Data showed that the investigational HIV vaccine regimen did not provide sufficient protection against HIV infection in a population of young women in sub-Saharan Africa at high risk of acquiring HIV. The vaccine candidate showed a favorable safety profile with no serious adverse events.
- Based on these results, the Imbokodo study will not continue, while further study analysis is ongoing.
- In parallel to the Phase 2b Imbokodo HIV vaccine trial, Janssen sponsored the ongoing Phase 3 Mosaico study. The study will test the safety and efficacy of a different composition of the HIV vaccine regimen among men who have sex with men (MSM) and transgender individuals.
- This study is being conducted in the Americas and Europe, where different strains of HIV are circulating.
- Price Action: JNJ stock is down 0.09% at $173.50 during the premarket session on the last check Tuesday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!